Insider Trading Alert - CYN, IBKR And OPK Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, Jan. 30, 2014, 67 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $700.00 to $562,013,038.08.

Highlighted Stocks Traded by Insiders:

City National (CYN) - FREE Research Report

Rosenblum Bruce who is Director at City National bought 500 shares at $72.72 on Jan. 30, 2014. Following this transaction, the Director owned 4,450 shares meaning that the stake was reduced by 12.66% with the 500-share transaction.

The shares most recently traded at $72.46, down $0.26, or 0.36% since the insider transaction. Historical insider transactions for City National go as follows:

  • 4-Week # shares sold: 6,876
  • 12-Week # shares sold: 6,876
  • 24-Week # shares sold: 6,876

The average volume for City National has been 262,000 shares per day over the past 30 days. City National has a market cap of $3.9 billion and is part of the financial sector and banking industry. Shares are down 8.7% year-to-date as of the close of trading on Thursday.

City National Corporation operates as the bank holding company for City National Bank that provides various banking, trust, and investment services to small to mid-sized businesses, entrepreneurs, professionals, and individuals. The stock currently has a dividend yield of 1.82%. The company has a P/E ratio of 18.1. Currently there are 3 analysts that rate City National a buy, 1 analyst rates it a sell, and 14 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on CYN - FREE

TheStreet Quant Ratings rates City National as a buy. The company's strengths can be seen in multiple areas, such as its expanding profit margins, solid stock price performance and increase in net income. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full City National Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Interactive Brokers Group (IBKR) - FREE Research Report

Nemser Earl H who is Vice Chairman at Interactive Brokers Group sold 15,349 shares at $21.29 on Jan. 30, 2014. Following this transaction, the Vice Chairman owned 114,192 shares meaning that the stake was reduced by 11.85% with the 15,349-share transaction.

Brody Paul Jonathan who is Chief Financial Officer at Interactive Brokers Group sold 8,534 shares at $21.29 on Jan. 30, 2014. Following this transaction, the Chief Financial Officer owned 63,487 shares meaning that the stake was reduced by 11.85% with the 8,534-share transaction.

The shares most recently traded at $21.15, down $0.14, or 0.68% since the insider transaction. Historical insider transactions for Interactive Brokers Group go as follows:

  • 4-Week # shares sold: 14,000
  • 12-Week # shares sold: 51,000
  • 24-Week # shares sold: 108,000

The average volume for Interactive Brokers Group has been 603,000 shares per day over the past 30 days. Interactive Brokers Group has a market cap of $1.1 billion and is part of the financial sector and financial services industry. Shares are down 12.65% year-to-date as of the close of trading on Thursday.

Interactive Brokers Group, Inc. operates as an automated electronic broker and market maker. The stock currently has a dividend yield of 1.88%. The company has a P/E ratio of 24.7. Currently there are 3 analysts that rate Interactive Brokers Group a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on IBKR - FREE

TheStreet Quant Ratings rates Interactive Brokers Group as a hold. The company's strengths can be seen in multiple areas, such as its solid stock price performance, revenue growth and reasonable valuation levels. However, as a counter to these strengths, we also find weaknesses including deteriorating net income, generally higher debt management risk and disappointing return on equity. Get the full Interactive Brokers Group Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Opko Health (OPK) - FREE Research Report

Frost Phillip Md Et Al who is CEO & Chairman at Opko Health bought 42,100 shares at $8.01 on Jan. 30, 2014. Following this transaction, the CEO & Chairman owned 138.6 million shares meaning that the stake was reduced by 0.03% with the 42,100-share transaction.

Hsiao Jane Ph D who is Vice Chairman & CTO at Opko Health bought 10,000 shares at $8.20 on Jan. 30, 2014. Following this transaction, the Vice Chairman & CTO owned 21.3 million shares meaning that the stake was reduced by 0.05% with the 10,000-share transaction.

The shares most recently traded at $7.93, down $0.27, or 3.4% since the insider transaction. Historical insider transactions for Opko Health go as follows:

  • 4-Week # shares bought: 10,000
  • 4-Week # shares sold: 46,730
  • 12-Week # shares bought: 10,000
  • 12-Week # shares sold: 46,730
  • 24-Week # shares bought: 10,000
  • 24-Week # shares sold: 46,730

The average volume for Opko Health has been 4.4 million shares per day over the past 30 days. Opko Health has a market cap of $3.3 billion and is part of the health care sector and health services industry. Shares are down 3.44% year-to-date as of the close of trading on Thursday.

Opko Health, Inc., a pharmaceutical and diagnostics company, engages in the discovery, development, and commercialization of novel and proprietary technologies. It operates in two segments, Pharmaceuticals and Diagnostics. Currently there are 3 analysts that rate Opko Health a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on OPK - FREE

TheStreet Quant Ratings rates Opko Health as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures and solid stock price performance. However, as a counter to these strengths, we also find weaknesses including feeble growth in the company's earnings per share, deteriorating net income and weak operating cash flow. Get the full Opko Health Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Data for this article provided by Zacks Investment Research

null

More from Markets

Week Ahead: Trade Fears and Stress Tests Signal More Volatility To Come

Week Ahead: Trade Fears and Stress Tests Signal More Volatility To Come

Trump Takes Aim at Auto Imports; Markets End Mixed -- ICYMI

Trump Takes Aim at Auto Imports; Markets End Mixed -- ICYMI

Video: What Oprah's Content Partnership With Apple Means for the Rest of Tech

Video: What Oprah's Content Partnership With Apple Means for the Rest of Tech

REPLAY: Jim Cramer on the Markets, Oil, Starbucks, Tesla, Okta and Red Hat

REPLAY: Jim Cramer on the Markets, Oil, Starbucks, Tesla, Okta and Red Hat

Flashback Friday: The Market Movers

Flashback Friday: The Market Movers